David Schlachet, Chairman of the Board
David Schlachet joined our board of directors in April 2014. He serves as a director of several public and private Israeli companies. He served as Chairman of Syneron Medical Ltd., an Israeli aesthetic medical device company, from 2013 to 2014. Prior to that, he served as Syneron Medical’s CEO from 2005 to 2007, after serving as its CFO in 2004. From 2008 to 2012, Mr. Schlachet served as a Director of the Tel Aviv Stock Exchange and Chairman of its Audit Committee. From 2000 to 2004, he served as a Managing Partner of Biocom, a venture capital fund specializing in the life sciences ﬁeld.
From 1995 to 2000, Mr. Schlachet served as the Senior Vice President and CFO of Strauss Elite Holdings, an Israeli packaged food group, and from 1997 to 2000 he served as active Chairman of Elite Industries, an Israeli coffee, confectionary, and salty snacks manufacturer. From 1988 until 1995, Mr. Schlachet served as Vice President of Finance and Administration of the Weizmann Institute of Science, Israel’s premier post-graduate scientiﬁc research institute, and as CEO of its technology transfer company, Yeda Research and Development Company, Ltd. Mr. Schlachet serves as a Director of Syneron Medical Ltd., EzChip Semiconductor Ltd., Taya Investments Ltd. (Chairman), Mazor Robotics Ltd., and BioCancell Ltd. Mr. Schlachet holds a B.Sc. degree in Chemical Engineering and an M.B.A. from Tel-Aviv University.
Adi Mohanty is the co-CEO of BioTime, Inc. since October 2015. He joined the company as its first COO in December 2014. He is also a director of BioTime’s company, OncoCyte Corporation. Mr. Mohanty was formerly with Shire, a biotechnology company focused on the research, development, and commercialization of novel biological products for rare diseases, where he served in a number of executive positions, including as President/Head of Regenerative Medicine from 2013 to 2014, as Senior Vice President, Business and Technical Operations, from 2012 to 2013, and as Global Franchise Head MPS from 2010 to 2012. Mr. Mohanty served as VP at Transkaryotic Therapies from 2002 to 2005, when it was acquired by Shire. Before joining Transkaryotic Therapies, Mr. Mohanty held a number of management positions in the Bioscience Division of Baxter Healthcare Corporation. Mr. Mohanty received an M.B.A. from Saint Mary’s College and has an M.S. and B.S. in Chemical Engineering.
Observer: Dr. Tamar Raz HBL
Dr. Tamar Raz is the CEO of Hadasit, the technology transfer company of Hadassah Medical Organization (HMO).
In her previous position, she served as VP of Marketing and Strategy of Ramot, the technology transfer company of Tel Aviv University, where she was responsible for the company’s strategic alliances and marketing activities.
Prior to joining Ramot in 2004, she directed the establishment and served as the CEO of Allergene, an Israeli startup company that was founded as an incubator project.